Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Sep;36(9):1922-7.
doi: 10.1128/AAC.36.9.1922.

Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa

Affiliations

Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa

Y Hirakata et al. Antimicrob Agents Chemother. 1992 Sep.

Abstract

We evaluated several potential effects of erythromycin (EM) on host defense systems and the virulence of Pseudomonas aeruginosa. Peritoneal macrophages obtained from mice given 250 mg of EM per kg of body weight for 7 days by the intraperitoneal, intravenous, subcutaneous, or oral route produced significantly greater amounts of thymocyte-activating factors. These data suggest that EM enhances the in vivo production of cytokines, such as interleukins 1 and 6. Treatment of P. aeruginosa D4 with subinhibitory concentrations of EM enhanced the association of bacteria with murine Kupffer cells in vitro and increased bacterial clearance from the blood in mice. EM suppressed the in vitro production of exotoxin A, total protease, elastase, and phospholipase C by P. aeruginosa D4; exotoxin A production by P. aeruginosa PA-103; and total protease production by P. aeruginosa B16 and PAO1 in a generally dose-dependent manner. These data demonstrate that EM produces various effects in addition to its direct antimicrobial activity, suggesting that it has potential as an immunomodulator or bacterial virulence-suppressing agent against P. aeruginosa and other infections.

PubMed Disclaimer

References

    1. Methods Enzymol. 1979;60:780-93 - PubMed
    1. Med Clin North Am. 1982 Jan;66(1):79-89 - PubMed
    1. Int J Immunopharmacol. 1990;12(1):31-6 - PubMed
    1. J Antimicrob Chemother. 1991 Mar;27(3):273-84 - PubMed
    1. Antimicrob Agents Chemother. 1989 Jan;33(1):41-7 - PubMed

MeSH terms

LinkOut - more resources